Evidence map›Paper›PMID 41563657›Full record

ArticleEndocrine2026

Endoscopic surgery for noninvasive prolactinomas: A large multicenter, single-arm, retrospective study (PRLomaSaR).

Yijun Cheng, Yu Wang, Wenwen Lv, Gang Yang, Yazhuo Zhang, Kaiyu Guo, Jing Xie, Hao Tang, Weiting Gu, Jing Guo and 10 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Yijun Cheng *Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197# Ruijin er road, Shanghai, 200025, China.
Yu Wang *Department of Neurosurgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wenwen Lv *Clinical Research Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Gang YangDepartment of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yazhuo ZhangDepartment of Neurosurgery, Beijing Tiantan Hospital affiliated to Capital Medical University, Beijing, China.
Kaiyu GuoDepartment of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Jing XieDepartment of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hao TangDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197# Ruijin er road, Shanghai, 200025, China.
Weiting GuDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197# Ruijin er road, Shanghai, 200025, China.
Jing GuoDepartment of Neurosurgery, Beijing Tiantan Hospital affiliated to Capital Medical University, Beijing, China.
Bo ZhangDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197# Ruijin er road, Shanghai, 200025, China.
Shaojian LinDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197# Ruijin er road, Shanghai, 200025, China.
Hong YaoDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197# Ruijin er road, Shanghai, 200025, China.
Li XueDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197# Ruijin er road, Shanghai, 200025, China.
Jian LiClinical Research Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Tao XieDepartment of Neurosurgery, Zhongshan Hospital affiliated to Fudan University, Shanghai, China.
Yuefei ZhouDepartment of Neurosurgery, Xijing Hospital, Air Force Military Medical University, Shanxi, China.
Chuzhong LiDepartment of Neurosurgery, Beijing Tiantan Hospital affiliated to Capital Medical University, Beijing, China. lichuzhong@ccmu.edu.cn.
Dakuan GaoDepartment of Neurosurgery, Xijing Hospital, Air Force Military Medical University, Shanxi, China. syjgdk@126.com.
Zhe Bao WuDepartment of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197# Ruijin er road, Shanghai, 200025, China. zhebaowu@aliyun.com.ORCID 0000-0002-1611-8228

Funding

Clinical Research Fund from Shanghai Municipal Health Commission 20224Y0027National Natural Science Foundation of China 82000749National Natural Science Foundation of China 82141114, 81972339National Natural Science Foundation of China 82201616Science and Technology Commission of Shanghai Municipality 22Y11904700
6 · The paper itself

Abstract

purposeTo determine the efficacy of endoscopic transsphenoidal surgery (TSS) in patients with noninvasive prolactinomas of Knosp grades 0–2.

methodsA retrospective analysis was performed in 90 patients from five centers who had noninvasive prolactinomas and underwent endoscopic TSS from January 2020 to April 2023. The hormone remission (HR) rates of prolactin (PRL) and potential variables affecting surgical outcomes were analyzed.

resultsAmong these 90 patients with prolactinomas, 1 patient was excluded because of loss to follow-up at 9 months. Among the 89 patients, 34 and 55 were males and females, respectively. There were 26 microadenomas and 63 macroadenomas. In terms of Knosp grade, 35, 36, and 18 cases were grade 0, 1, and 2, respectively. The total HR rate at 1 year after surgery was 89.89% (80/89). Specifically, the HR rates of patients with microadenomas and macroadenomas were 96.15% and 87.30%, respectively. The HR rates for patients with Knosp grades 0, 1, and 2 tumors were 94.24%, 83.33%, and 94.44%, respectively. Different variables, including age, sex, tumor size, Knosp grade, preoperative PRL levels, and medical history, were not different between the surgery-induced HR and non-HR groups. Postoperative complications included 3.37% CSF leakage, 1.12% permanent hypopituitarism, and 4.49% diabetes insipidus.

conclusionEndoscopic TSS can be performed as an effective treatment strategy for noninvasive prolactinomas at the Pituitary Adenoma Center of Excellence.

Indexed as

EndoscopyNeuroendoscopyPituitary NeoplasmsProlactinomaAdultAgedFemaleHumansMaleMiddle AgedProlactinRetrospective StudiesTreatment OutcomeProlactinCabergolineEndoscopic transsphenoidal surgeryHormone remissionKnosp gradeProlactinoma

Identifiers

PMID41563657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.